Median Technologies Aims for FDA Clearance as eyonis® LCS Lung Cancer Screening Nears Commercialization
Event summary
- Median Technologies reports €23.5M revenue in 2025, up 2.6% YoY, with iCRO backlog hitting €76.6M.
- FDA decision on eyonis® LCS 510(k) clearance expected in weeks, CE marking in Q2 2026.
- First U.S. distribution agreement signed for eyonis® LCS, with additional deals in discussions.
- Cash position strengthened to €18.2M, supported by €61.4M refinancing in 2025.
The big picture
Median Technologies is positioning itself as a leader in AI-driven early cancer diagnosis, with eyonis® LCS poised to disrupt lung cancer screening. The company’s strong iCRO backlog and refinancing efforts provide financial stability as it navigates regulatory milestones. Success hinges on executing its commercial strategy while maintaining operational efficiency in a competitive oncology diagnostics market.
What we're watching
- Regulatory Approval
- Whether the FDA and CE marking decisions will proceed as scheduled and enable a smooth commercial rollout of eyonis® LCS.
- Commercial Expansion
- The pace at which Median can secure additional distribution agreements and scale eyonis® LCS adoption in the U.S. and Europe.
- Operational Efficiency
- How Median’s ongoing automation and organizational optimization efforts will impact iCRO’s profitability and growth trajectory.
Related topics